Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hyperglycemia Overview 6 Therapeutics Development 7 Pipeline Products for Hyperglycemia - Overview 7 Pipeline Products for Hyperglycemia - Comparative Analysis 8 Hyperglycemia - Therapeutics under Development by Companies 9 Hyperglycemia - Therapeutics under Investigation by Universities/Institutes 10 Hyperglycemia - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Hyperglycemia - Products under Development by Companies 13 Hyperglycemia - Products under Investigation by Universities/Institutes 14 Hyperglycemia - Companies Involved in Therapeutics Development 15 Kissei Pharmaceutical Co., Ltd. 15 Mitsubishi Tanabe Pharma Corporation 16 PhaseBio Pharmaceuticals, Inc. 17 Hyperglycemia - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 CDR-267F018 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 FGH-10019 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 KR-62980 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 PE-0139 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Peptides to Antagonize Glucagon Receptor for Type 2 Diabetes and Hyperglycemia - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Hyperglycemia - Recent Pipeline Updates 40 Hyperglycemia - Dormant Projects 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44

Kissei Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation PhaseBio Pharmaceuticals, Inc.